Cancer gene therapy by adenovirus vectors (Advs) for metastatic cancer is limited because systemic administration of Adv produces low therapeutic effect and severe side effects. In this study, we generated a dual cancer-specific targeting vector system by using PEGylation and the telomere reverse transcriptase (TERT) promoter and attempted to treat experimental metastases through systemic administration of the vectors. We first optimized the molecular size of PEG and modification ratios used to create PEG-Ads. Systemic administration of PEG-Ad with 20-kDa PEG at a 45% modification ratio (PEG[20K/45%]-Ad) resulted in higher tumor-selective transgene expression than unmodified Adv. Next, we examined the effectiveness against metastases and side effects of a TERT promoterdriven PEG[20K/45%]-Ad containing the herpes simplex virus thymidine kinase (HSVtk) gene (PEG-Ad-TERT/ HSVtk). Systemic administration of PEG-Ad-TERT/HSVtk showed superior antitumor effects against metastases with negligible side effects. A cytomegalovirus (CMV) promoter-driven PEG[20K/45%]-Ad also produced antimetastatic effects, but these were accompanied by side effects. Combining PEG-Ad-TERT/HSVtk with etoposide or 5-fluorouracil enhanced the therapeutic effects with negligible side effects. These results suggest that modification with 20-kDa PEG at a 45% modification ratio is the optimal condition for PEGylation of Adv, and PEG-Ad-TERT/HSVtk is a prototype Adv for systemic cancer gene therapy against metastases.
Introduction
Gene therapy is expected to have a key function in nextgeneration cancer therapy. The adenovirus vector (Adv) is one of the most frequently used vectors in cancer gene therapy. [1] [2] [3] In several clinical trials, intratumoral injection of Adv has shown therapeutic efficacy against primary tumors.
4,5 However, successful cancer gene therapy requires treatment of not only the primary tumor, but also distant metastases. To treat metastases, Adv must be administered systemically, but the accumulation of and gene expression from Adv must be restricted to the tumor cells. Unfortunately, it is difficult to treat metastases with Adv because of low accumulation and transgene expression of Adv in tumors after systemic administration. Moreover, systemic administration of Adv leads to acute accumulation and transgene expression in the liver, which may cause considerable toxicity. 6 For this reason, there are few reports of successful treatment of disseminated metastases using Adv.
One of the most useful ways to control the in vivo pharmacokinetics of proteins, liposomes, and Adv is to conjugate them chemically to polyethleneglycol (PEG). 7, 8 Covalent conjugation to PEG (PEGylation) can prolong the plasma half-life, and alter the tissue distribution of the conjugates compared with the native form. The extended circulating lifetime in blood induces the enhanced permeability and retention (EPR) effect, which is based on the leaky nature of the tumor blood vessels, resulting in increased delivery of the conjugates to tumor tissue. 9 In detail, compared with those in normal tissues, the blood vessels in tumor tissues are irregular in shape, dilated, leaky, or defective, and tumor tissues have poor lymphatic drainage. 10 This anatomical defectiveness and the functional abnormalities result in extensive leakage of blood plasma components, such as macromolecules, nanoparticles, and lipidic particles, into the tumor tissue.
Moreover, the slow venous return in tumor tissue and the poor lymphatic clearance mean that large molecules are retained in the tumor, whereas extravasation into tumor interstitium continues. 9 We have examined the characteristics of PEGylated Adv (PEG-Ad) using 5-kDa PEG (PEG[5K]-Ad). With optimized modification conditions, PEG[5K]-Ad showed higher accumulation and transgene expression in tumors than unmodified Adv after systemic administration because of the EPR effect. 11 Furthermore, we showed that PEG[5K]-Ad encoding a therapeutic gene produced both stronger tumor-suppressive activity and fewer hepatotoxicity than unmodified Adv, suggesting that systemic administration of PEG[5K]-Ad has great potential as a vector for systemic cancer gene therapy. 11 However, the accumulation and transgene expression of PEG[5K]-Ad in liver are still high, and PEG[5K]-Ad does induce side effects. Therefore, it is necessary to develop a novel PEG-Ad with similar transgene expression in tumors, but lower transgene expression in normal organs, including liver, than PEG[5K]-Ad.
Tumor-specific promoter systems are considered as another promising approach for overcoming the hepatotoxicity induced by systemic administration of Adv. Unlike the constitutively active cytomegalovirus (CMV) promoter typically used in Adv, the human telomere reverse transcriptase (TERT) promoter regulates transgene expression at the transcriptional level.
12,13 The TERT promoter was recently shown to restrict the expression of various therapeutic genes, including herpes simplex virus thymidine kinase (HSVtk), after intratumoral injection into telomerase-positive tumor cells.
14 However, high doses of TERT promoter-driven Adv (Ad-TERT) were required to sustain gene expression in the tumor after systemic administration for antitumor effects because of its low accumulation in the tumor, and these high doses of Adv induced severe side effects because of the accumulation of Adv itself in normal tissues, thus destroying the normal cells and activating the innate immune response. 15 Thus, the TERT-promoter system could represent a promising approach with potential application in targeted cancer gene therapy, but it requires further improvement for tumor selectivity.
In this study, we generated a dual cancer-specific targeting vector system by using PEGylation for transductional targeting and TERT promoter for transcriptional targeting. We first optimized the PEG-Ad for passive targeting to tumors. Next, we examined the therapeutic effects against metastases and side effects of systemically administered PEGylated TERT promoterdriven Adv.
Results
Optimization of the molecular weight of PEG Earlier, we showed that PEG[5K]-Ad at a modification ratio of about 90% (PEG[5K/90%]-Ad) enables high gene expression in tumors after intravenous injection. 11 However, how the molecular size of the PEG affected the in vivo transduction of PEG-Ad was unknown. To construct a novel PEG-Ad that is more efficient and safe than PEG[5K/90%]-Ad, we constructed PEG-Ads with 2-and 20-kDa PEG at 30, 60, and 80% modification ratios, using Adv-expressing luciferase. The PEG modification ratio was determined by SDS-PAGE as reported earlier.
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To investigate the effect of PEGylation on in vitro transduction, we transduced A549 cells with each PEGAd. The luciferase expression from PEG-Ads decreased as the PEG modification ratio and molecular weight of PEG increased (Figure 1a ). Systemic administration of Adv leads to acute accumulation and transgene expression in the liver, which may cause considerable toxicity. Therefore, to investigate the in vivo transduction, we compared the luciferase expression of each PEG-Ad in tumor and liver after intravenous injection into Meth-A-bearing mice. The vector dose of 1 Â 10 10 virus particles (vp) was selected because this dose did not induce any apparent toxicity with unmodified Adv. The luciferase expression of PEG[2K]-Ads in tumor and liver was lower than that of unmodified Adv at each modification ratio (Figure 1b 
Innate immune response against PEG[20K/45%]-Ad
The systemic administration of Adv results in the initiation of a strong innate immune response and inflammation, 16 
Luciferase expression pattern of PEG-Ad-TERT in metastasis
Next, to assess the effect of using PEGylation and the TERT promoter in combination, we constructed Advexpressing luciferase under the control of the CMV or TERT promoter (Ad-CMV/Luc, Ad-TERT/Luc), and PEG-Ad-CMV/Luc and PEG-Ad-TERT/Luc using 20-kDa PEG with a 45% modification ratio. We used immunohistochemistry to compare the luciferase expression in an experimental CT26.CL25-cell metastasis model after systemic administration of the vector ( Figure 3 ). The lungs of mice bearing established pulmonary metastases showed obvious metastatic regions with massive colonies. In pulmonary colonies, luciferase expression was detected as brown areas in all Adv- Therapeutic effect of PEGylated adenovirus vector X Yao et al treated mice. Transgene expression of PEG-Ad-TERT/ Luc was almost the same as that of PEG-Ad-CMV/Luc in metastatic colonies, although it is difficult to observe differences in luciferase expression among mice in this assay. In liver, massive luciferase expression was observed in mice treated with Ad-CMV/Luc, and 
Therapeutic effect of PEG-Ad-TERT/HSVtk on metastases
To evaluate the effectiveness of combining PEGylation and the TERT promoter as a cancer therapy, we assessed the therapeutic effect of intravenous injections of PEG-Ad-TERT against metastases. Here, we used Advexpressing HSVtk as the therapeutic gene; HSVtk is an enzyme that can convert the nontoxic, clinically used antiviral drug ganciclovir (GCV) into a highly cytotoxic form. 17, 18 We constructed PEG-Ad-TERT/HSVtk or PEGAd-CMV/HSVtk using 20-kDa PEG with a 45% modification ratio. In a CT26.CL25-cell metastasis model, we administered 5 Â 10 10 vp of these Advs to mice intravenously and assessed the therapeutic effect (Figures 4a and b) . Multiple metastatic colonies were observed in the lungs of mice treated with PEGAd-TERT/HSVtk without GCV, GCV only, Ad-CMV/ HSVtk, or Ad-TERT/HSVtk, comparable to the number in untreated mice. In contrast, we observed reduced numbers of metastatic colonies in the lungs of mice treated with PEG-Ad-CMV/HSVtk and PEG-Ad-TERT/ HSVtk. We evaluated the therapeutic effects of the Advs by measuring lung weight, because mice with lung metastases show increased lung weight. Lung weight was significantly lower in mice treated with PEGAd-CMV/HSVtk and PEG-Ad-TERT/HSVtk than in untreated mice (Figure 4b ). Next, we assessed the therapeutic effect of systemically administered PEGAd-TERT/HSVtk on the experimental metastasis of mouse melanoma B16BL6 cells (Figures 4c and d) . Injection of PEG-Ad-TERT/HSVtk reduced the numbers of metastatic colonies in lung compared with the number in untreated mice, consistent with the CT26.CL25 results, whereas PEG-Ad-TERT/HSVtk without GCV, GCV only, and Ad-TERT/HSVtk did not induce any therapeutic effect. We also evaluated side effects by measuring body weights and glutamic oxaloacetic transaminase (GOT) and glutamic-pyruvic transaminase (GPT) levels in the blood of CT26.CL25-treated mice. Injection of Ad-CMV/ HSVtk induced a significant loss of body weight and elevated GOT/GPT activity (Figures 5a and b) . In addition, PEG-Ad-CMV/HSVtk induced a slight, but substantial elevation of GOT/GPT activity compared with that of normal mice. In contrast, intravenous injection of PEG-Ad-TERT/HSVtk did not increase the GOT/GPT level. These data suggest that PEG-Ad-TERT/ ) for 7 days. On day 14 after the CT26.CL25 injection, lungs were harvested and the therapeutic effects were assessed by (a) examining photographs of the lungs and (b) weighing the lungs. B16BL6 cells were injected intravenously into C57BL6 mice through the tail vein and 5 Â 10 10 vp of Advs were injected intravenously on day 7 after the B16BL6 injection. After the Adv injection, the mice received daily intraperitoneal injections of GCV (50 mg kg -1 ) for 7 days. On day 14 after the B16BL6 injection, lungs were harvested and the therapeutic effects were assessed by (c) examining photographs of the lungs and (d) counting the number of metastatic colonies in the lungs. All data are presented as means ± s.d. (n ¼ 5-6; *Po0.05, **Po0.01 versus value for PBS-treated group by ANOVA).
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HSVtk would be a prototype vector with suitable efficacy and safety for systemic cancer gene therapy against metastases.
Combination effect of PEG-Ad-TERT/HSVtk and an anticancer drug
To decrease the dose of PEG-Ad-TERT/HSVtk without suppressing the therapeutic effect, we evaluated the therapeutic effect of PEG-Ad-TERT/HSVtk in combination with a clinically used anticancer drug, either etoposide or 5-fluorouracil (5-FU). We reduced the dose from the 5 Â 10 10 vp per mouse used in the single-agent experiments shown in Figures 4 and 5 to 1 Â 10 10 vp per mouse in this experiment. In the B16BL6 metastatic model, mice were given 1 Â 10 10 vp PEG-Ad-TERT/ HSVtk intravenously and then 2 mg kg -1 etoposide or 10 mg kg -1 5-FU intraperitoneally for 7 consecutive days. PEG-Ad-TERT/HSVtk in combination with etoposide or 5-FU synergistically and significantly suppressed the metastasis compared with PEG-Ad-TERT/HSVtk, whereas etoposide or 5-FU alone had no antitumor effects (Figures 6a and b) . These results suggest that PEG-Ad-TERT/HSVtk combined with etoposide or 5-FU could provide enhanced therapeutic effects at decreased doses of PEG-Ad-TERT/HSVtk to avoid the occurrence of side effects.
Discussion
In principle, viral vector-based gene therapies should be effective options for treating neoplastic diseases. However, in reality, these approaches have not proven as successful as originally intended or envisioned. Therefore, it is necessary to develop novel gene therapy systems for treatment of resectable primary cancers and metastatic cancers. In this study, to achieve these objectives, we generated a dual cancer-specific targeting vector system by using PEGylation for transductional targeting and the TERT promoter for transcriptional targeting.
The molecular weight of PEG and the PEG modification ratio significantly affects the characteristics of conjugates. 19 A recent study showed that the modification of Adv with 20-kDa PEG decreased liver transduction in vivo compared with modification with 5-kDa PEG. 20, 21 However, no study has investigated the optimal PEGylation conditions for tumor targeting. We first examined the correlation between PEG modification and gene expression patterns and showed that PEG[20K/45%]-Ad was the optimal condition for PEGylation of Adv for tumor-selective gene expression (Figure 1 Therapeutic effect of PEGylated adenovirus vector X Yao et al ance of Adv from blood circulation after intravenous injection is mostly caused by rapid uptake into the hepatocytes or Kupffer cells in liver. 22 Therefore, the retention time of Adv in the blood must be prolonged for treatment of disseminated targets such as distant metastases. Our results suggest that the modification of Adv with 20-kDa PEG at a 45% modification ratio strongly suppresses the transition into the liver, thereby prolonging the circulating lifetime and leading to the accumulation of Adv in the tumor because of the EPR effect. In addition, various serum proteins bind to the Adv surface and may serve as a bridge to receptors on hepatocytes. 23, 24 The large 20-kDa PEG likely covers a larger area of the Adv surface than do smaller forms of PEG, and thereby prevents binding of blood factors that would otherwise mediate liver transduction.
Unresectable cancers remain the major cause of morbidity and mortality in cancer patients and are one of the most formidable problems in clinics. In lung cancer, for example, despite the use of chemotherapy and radiation therapy in combined-modality protocols, local control rates are o20%. First, we confirmed high transgene expression of PEG-Ad-TERT/Luc in tumors, including metastases, without expression in nontarget tissue such as liver (Figures 1c and 3) . Then, we attempted to treat metastases with PEG[20K/45%]-Ad-TERT/HSVtk through systemic administration. Many studies, including human clinical trials using HSVtkexpressing Adv, have confirmed the efficacy of this gene therapy approach when delivered through intratumoral injection. 15, [25] [26] [27] [28] However, few studies have evaluated the usefulness of this system to treat metastases through Therapeutic effect of PEGylated adenovirus vector X Yao et al intravenous injection. We showed that PEG-Ad-TERT/ HSVtk induced strong antitumor effects against metastases without side effects, although PEG-Ad-CMV/ HSVtk did induce significant side effects in spite of strong antitumor effects (Figures 4 and 5) . Research on stealth liposome or polymer conjugates such as SMANCS 29 has revealed that the EPR effect is commonly observable in most solid tumors, whether primary or metastatic in nature. Therefore, we believe that in this study PEG-Ad-TERT/HSVtk accumulated specifically in metastatic colonies because of the EPR effect, in which it induced strong antitumor effects. In addition, unlike the CMV promoter, the TERT promoter restricts transgene expression to tumor cells only. Earlier, we showed that Ad-TERT reduces transgene expression in normal organs, but not in tumors after systemic administration of Adv in mice bearing solid tumors. 15 We consider that the strong antitumor effect of PEG-Ad-TERT/HSVtk without side effects is based on the combination of transductional targeting using PEGylation and transcriptional targeting using the TERT promoter.
One of the hurdles confronting Adv-mediated gene transfer is that infection with Adv is dependent on the presence of the coxsackievirus and adenovirus receptor (CAR, the primary receptor for Adv) on the target cells. 30 As many tumor cells that are targets for gene therapy, including melanoma cells, express no or little CAR, it is difficult to achieve sufficient gene expression for a therapeutic effect. [31] [32] [33] Importantly, PEG-Ad-TERT/ HSVtk induced significant therapeutic effects against metastatic B16BL6 and CT26.CL25 cells, which are CARnegative cells, 34 whereas PEG[20K/45%]-Ad showed significantly reduced CAR-dependent transgene expression in vitro compared with unmodified Adv, because the interaction of Adv and CAR was inhibited by the steric hindrance of PEG chains. 35 As the nonspecific endocytotic activity of tumor tissue is enhanced in general compared with that of normal tissue, we think that the accumulation and retention of PEG[20K/45%]-Ad in the tumor tissue induced its efficient uptake.
The other main hurdle for systemic administration of Adv is that systemic injection of Adv induces undesired innate immunity. 36, 37 Macrophages in the liver or spleen efficiently take up Adv; this results in strong activation of the immune response. 38 PEGylation of Adv decreases the innate immune responses, 35, 39, 40 and PEG[20K/45%]-Ad reduced the innate immune responses after systemic administration (Figure 2c ). This reduced innate immune response is likely to be correlated with a reduction in vector uptake by macrophages. Therefore, PEG-Ad-TERT could be an effective vector for tumor-selective gene transfer through systemic administration without toxicity because of immune responses.
The Adv dose of 5 Â 10 10 vp in a mouse is approximately equivalent to a dose of 1 Â 10 14 vp in a human. Despite the reduction of the immune response with PEGAd-TERT, this high Adv dose carries tremendous clinical risk of inducing immune responses, as occurred in the death of the University of Pennsylvania patient in 1999 after an injection of 4 Â 10 13 vp of Adv. 36, 37 Therefore, we attempted to reduce the dose of Adv by combining it with an anticancer drug. PEG-Ad-TERT/HSVtk at 1 Â 10 10 vp induced strong antitumor effects without side effects when combined with etoposide or 5-FU, whereas PEG-Ad-TERT/HSVtk at 1 Â 10 10 vp alone did not induce any therapeutic effects ( Figure 6 ). Therefore, combining PEG-Ad-TERT/HSVtk with etoposide or 5-FU was very useful for reducing the required dose of Adv, although the precise mechanism of the combination effect needs to be examined. 41, 42 Furthermore, 5-FU resistance has been reported, 43 and combined treatment may diminish the risk of acquired drug resistance that is likely in single-agent-based treatments.
In this study, we succeeded in generating a dual cancer-specific targeting vector system by using PEGylation and the TERT promoter. In addition, we showed that PEG-Ad-TERT/HSVtk with 20-kDa PEG at a 45% modification ratio had antitumor effects against metastases when administered systemically. Thus, PEG-Ad-TERT/HSVtk should be useful as a platform vector for cancer gene therapy.
Materials and methods

Mice and cells
BALB/c mice and C57BL6 mice were purchased from SLC Inc. (Hamamatsu, Japan). All of the animal experimental procedures were performed in accordance with the Osaka University guidelines for the welfare of animals. CT26.CL25 cells (murine colon carcinoma cells) were provided by Professor NP Restifo (National Cancer Institute, Bethesda, MD, USA). A549 cells (human lung carcinoma cells) were purchased from American Type Culture Collection (Manassas, VA, USA). Meth-A fibrosarcoma cells were provided by Mochida Pharmaceutical Company (Tokyo, Japan). CT26.CL25 cells were cultured in RPMI (Sigma-Aldrich, St Louis, MO, USA) containing 10% FBS, 2 mM L-glutamine, and antibiotics. B16BL6 cells were cultured in minimal essential medium (SigmaAldrich) containing 7.5% FBS and antibiotics.
Construction of Adv
An improved in vitro ligation method 15, [44] [45] [46] was used to construct Adv-expressing firefly luciferase or HSVtk under the control of the CMV or TERT promoter (Ad-CMV/Luc, Ad-CMV/HSVtk, Ad-TERT/Luc, and Ad-TERT/HSVtk). Each Adv was generated using established methods. 11 The vp and biological titer were determined as described. 11, 15 The ratio of the particleto-biological titer was between 10 and 40.
PEGylation of Adv
Methoxy-polyethyleneglycol-succinimidyl propionate (mPEG-SPA; molecular weight, 2000, 5000, or 20000; Nektar, San Carlos, CA, USA) was used for PEGylation. Adv was incubated with mPEG-SPA at 37 1C for 45 min with gentle stirring. The modification ratio of PEG-Ad was determined by SDS-PAGE analysis as reported earlier.
11,47
Adv-mediated transduction in vitro 
Adv-mediated transduction in vivo
Mice bearing Meth-A fibrosarcoma cells were intravenously administered 10 10 vp of unmodified Adv or PEGAds encoding the luciferase gene after the tumor diameter had reached about 8 mm. The tumor and liver were harvested 48 h after the injection and luciferase activity was measured. To evaluate transgene expression in a metastasis model in vivo, CT26.CL25 cells were injected into the tail veins of 5-week-old BALB/c mice. After 12 days, the mice were intravenously administered 5 Â 10 10 vp of various Advs encoding the luciferase gene. The lungs and livers were harvested 48 h after injection and fixed in 4% paraformaldehyde. Frozen sections were prepared and incubated with an anti-Luciferase pAntibody (Promega) and then with a biotinylated secondary antibody and the avidin-biotin-peroxidase complex (DAKO, Carpinteria, CA, USA).
Blood clearance of unmodified and PEG-Ad
Blood clearance of each Adv was determined using real-time quantitative polymerase chain reaction (PCR). In brief, blood samples were collected by retro-orbital bleeding at various times (15, 30 , and 60 min) after intravenous administration of 10 10 vp of unmodified Adv or PEG-Ads in 6-week-old BALB/c mice. Total DNA, including Adv DNA, from whole blood was extracted. The number of viral genomes was measured by real-time quantitative PCR as described. 11 
Tissue distributions of unmodified and PEG-Ad
Once the tumor diameter was about 8 mm, Meth-Abearing mice were intravenously administered 10 10 vp of unmodified Adv or each PEG-Ad encoding the luciferase gene. The tumor and liver were harvested 6 h after the injection and DNA was extracted. The number of viral genomes in each sample was measured by real-time quantitative PCR as described.
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Cytokine measurement BALB/c mice were intravenously administered PBS or 5 Â 10 10 vp of Ad-TERT or PEG-Ad-TERT. Blood samples were collected 6 h after the intravenous injection. The levels of IL-6 and IL-12p40 in the plasma were measured using an ELISA kit (BD Biosciences, for IL-6; eBiosience, for IL-12) according to the manufacturers' instructions.
Gene therapy to metastasis-bearing mice CT26.CL25 or B16BL6 cells (3 Â 10 5 cells per mouse) were injected into the tail vein of 5-week-old BALB/c mice or C57BL/6 mice, respectively. After 7 days, Advs at 5 Â 10 10 vp were intravenously injected into the mice. After Adv injection, the mice received daily intraperitoneal injections of GCV (50 mg kg -1 ) for 7 days. Serum levels of GOT and GPT, used as indicators of hepatotoxicity, were measured on day 7 after Adv injection by using the Transaminase CII test (Wako, Osaka, Japan) according to the manufacturer's instructions. On the same day, lungs and livers were harvested and weighed.
Combination therapy with an anticancer drug to metastasis-bearing mice B16BL6 cells (3 Â 10 5 cells per mouse) were injected into the tail vein of 5-week-old C57BL/6 mice. After 7 days, established metastasis-bearing mice were intravenously administered 1 Â 10 10 vp PEG-Ad-TERT/HSVtk or PBS. After the injection, the mice received daily intraperitoneal injections of GCV (50 mg kg -1 ) for 7 days, combined with etoposide (2 mg kg -1 ) or 5-FU (10 mg kg -1 ). On day 7 after the injection, the lungs were harvested and fixed in Bouin's solution for 24 h. The metastatic colonies on the surface were counted.
Statistical analysis
All results are expressed as mean ± s.d. Differences were compared using Student t-tests or Bonferroni's method after analysis of variance (ANOVA).
